医生是否有义务与患者讨论扩大对研究性药物的获取途径？一种规范分析。
Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis.
机构信息
DEPARTMENT OF MEDICAL ETHICS, PHILOSOPHY AND HISTORY OF MEDICINE, ERASMUS MC, UNIVERSITY MEDICAL CENTRE ROTTERDAM, THE NETHERLANDS.
GGZ BREBURG, TILBURG, THE NETHERLANDS.
出版信息
J Law Med Ethics. 2023;51(1):172-180. doi: 10.1017/jme.2023.53. Epub 2023 May 25.
Abstract
Drawing on ethical and legal frameworks in the Netherlands, the United States and France, we examine whether physicians are expected to inform patients about potentially relevant opportunities for expanded access to investigational drugs. While we found no definitive legal obligation, we argue that physicians have a moral obligation to discuss opportunities for expanded access with patients who have run out of treatment options to prevent inequality, to promote autonomy, and to achieve beneficence.
摘要
借鉴荷兰、美国和法国的伦理和法律框架，我们考察了医生是否有责任告知患者潜在的扩大获取研究性药物的机会。虽然我们没有发现明确的法律义务，但我们认为，医生有道德义务与已经用尽治疗选择的患者讨论扩大获取机会，以防止不平等，促进自主性，并实现善行。
相似文献
1
Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis.
J Law Med Ethics. 2023;51(1):172-180. doi: 10.1017/jme.2023.53. Epub 2023 May 25.
2
The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.
J Med Philos. 2020 Mar 19;45(2):193-211. doi: 10.1093/jmp/jhz038.
3
What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
BMC Med Ethics. 2019 Nov 9;20(1):80. doi: 10.1186/s12910-019-0420-8.
4
Devil in the Details: Physician Duties and Expanded Access.
J Law Med Ethics. 2023;51(1):181-184. doi: 10.1017/jme.2023.54. Epub 2023 May 25.
5
The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians' Views and Experiences in The Netherlands.
J Bioeth Inq. 2021 Jul;18(2):319-334. doi: 10.1007/s11673-021-10090-7. Epub 2021 Feb 15.
6
Is procreative beneficence obligatory?
J Med Ethics. 2015 Feb;41(2):175-8. doi: 10.1136/medethics-2013-101711. Epub 2014 Feb 12.
7
The ethical and legal framework for the decision not to resuscitate.
West J Med. 1984 Jan;140(1):117-22.
8
Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
Health Policy. 2018 Sep;122(9):977-983. doi: 10.1016/j.healthpol.2018.06.005. Epub 2018 Jun 18.
9
Professional ethics in extreme circumstances: responsibilities of attending physicians and healthcare providers in hunger strikes.
Theor Med Bioeth. 2015 Aug;36(4):249-63. doi: 10.1007/s11017-015-9333-9.
10
An obligation to provide abortion services: what happens when physicians refuse?
J Med Ethics. 1996 Apr;22(2):115-20. doi: 10.1136/jme.22.2.115.
引用本文的文献
1
Devil in the Details: Physician Duties and Expanded Access.
J Law Med Ethics. 2023;51(1):181-184. doi: 10.1017/jme.2023.54. Epub 2023 May 25.
本文引用的文献
1
The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.
Med Health Care Philos. 2022 Dec;25(4):693-701. doi: 10.1007/s11019-022-10106-y. Epub 2022 Aug 11.
2
ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study.
J Med Internet Res. 2021 Oct 28;23(10):e26890. doi: 10.2196/26890.
3
[Expanded Access in The Netherlands: prescribing unregistered medicine].
Ned Tijdschr Geneeskd. 2021 Feb 25;165:D5168.
4
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
Drug Discov Today. 2021 Feb;26(2):593-603. doi: 10.1016/j.drudis.2020.11.025. Epub 2020 Nov 27.
5
Medicine's collision with false hope: The False Hope Harms (FHH) argument.
Bioethics. 2020 Sep;34(7):703-711. doi: 10.1111/bioe.12731. Epub 2020 Mar 5.
6
Cystic Fibrosis Lung Disease: An Overview.
Respir Care. 2020 Feb;65(2):233-251. doi: 10.4187/respcare.06697. Epub 2019 Nov 26.
7
What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
BMC Med Ethics. 2019 Nov 9;20(1):80. doi: 10.1186/s12910-019-0420-8.
8
New drugs: where did we go wrong and what can we do better?
BMJ. 2019 Jul 10;366:l4340. doi: 10.1136/bmj.l4340.
9
Ethics codes and use of new and innovative drugs.
Br J Clin Pharmacol. 2019 Mar;85(3):501-507. doi: 10.1111/bcp.13833. Epub 2019 Jan 4.
10
Pre-approval Access Terminology: A Cause for Confusion and a Danger to Patients.
Ther Innov Regul Sci. 2017 Jul;51(4):494-500. doi: 10.1177/2168479017696267. Epub 2017 Mar 3.
Zotero 插件